CZ
3
Active Trials
14
Total Trials
0
Organizations
1
Events
Czechia
Medical Only (Private)
Reimbursed Care Access
As of early 2026 Czechia permits tightly regulated medical use of psilocybin and has registered esketamine (Spravato); ketamine is widely used off‑label in psychiatry (mostly outside full public reimbursement). Other classical psychedelics (MDMA, DMT and derivatives, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) remain scheduled/controlled and are only available within authorised research or otherwise prohibited contexts under the narcotics law framework.